{"analyses":[{"ciLowerLimit":"-0.009","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.0234","groupDescription":"Troponin I ng/mL, baseline versus end study levels.","groupIds":["OG000"],"nonInferiorityComment":"P-values and confidence intervals are not adjusted for multiple testing","nonInferiorityType":"OTHER","pValue":"0.340","paramType":"Mean outcome change","paramValue":"0.0072","statisticalComment":"degrees of freedom = 12","statisticalMethod":"Mixed Models Analysis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.07","value":"0.15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Cardiac biomarkers (BNP, Troponin I) were assessed at baseline, 6 and 12 months, with change at change at end of study reported","dispersionType":"Standard Deviation","groups":[{"description":"Patients with predominant amyloid involvement of the heart.","id":"OG000","title":"Cardiomyopathy"}],"paramType":"MEAN","populationDescription":"Patients with predominant amyloid involvement of the heart.","reportingStatus":"POSTED","timeFrame":"12 months","title":"Amyloid Cardiomyopathy: Troponin I","type":"PRIMARY","unitOfMeasure":"ng/mL"}